-
Je něco špatně v tomto záznamu ?
Effect of macitentan on hospitalizations: results from the SERAPHIN trial
RN. Channick, M. Delcroix, HA. Ghofrani, E. Hunsche, P. Jansa, FO. Le Brun, S. Mehta, T. Pulido, LJ. Rubin, BK. Sastry, G. Simonneau, O. Sitbon, R. Souza, A. Torbicki, N. Galiè,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- antagonisté endotelinového receptoru A aplikace a dávkování MeSH
- aplikace orální MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- familiární plicní arteriální hypertenze farmakoterapie patofyziologie MeSH
- hospitalizace trendy MeSH
- lidé středního věku MeSH
- lidé MeSH
- plicní tlak v zaklínění účinky léků MeSH
- progrese nemoci MeSH
- pyrimidiny aplikace a dávkování MeSH
- senioři MeSH
- sulfonamidy aplikace a dávkování MeSH
- výsledek terapie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
OBJECTIVES: This study sought to evaluate the effect of macitentan on hospitalization of patients with symptomatic pulmonary arterial hypertension (PAH). BACKGROUND: PAH is a progressive, life-threatening disease often requiring hospitalization. METHODS: In the multicenter, double-blind, randomized, event-driven, phase III SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) trial, patients with symptomatic PAH were randomized (1:1:1) to receive placebo or 3 mg or 10 mg of macitentan. Effects of macitentan on the risk, rate, and number of hospital days for all-cause and PAH-related hospitalizations were compared with those for placebo. Risk and causes of hospitalizations unrelated to PAH were investigated. RESULTS: Of 742 randomized patients, 250 received placebo, 250 received 3 mg of macitentan, and 242 received 10 mg of macitentan; the overall median duration of treatment was 115 weeks. Risk of all-cause hospitalization was reduced by 18.9% (p = 0.1208) and 32.3% (p = 0.0051) in the macitentan 3-mg and 10-mg arm, respectively. Rates of all-cause hospitalizations and numbers of hospital days were reduced by 20.5% (p = 0.0378) and 30.6% (p = 0.0278), respectively, with 3 mg of macitentan and by 33.1% (p = 0.0005) and 31.0% (p = 0.0336), respectively, with 10 mg of macitentan. Risk of PAH-related hospitalizations were reduced by 42.7% (p = 0.0015) and 51.6% (p < 0.0001) in the macitentan 3-mg and 10-mg arms, respectively. Rate of PAH-related hospitalizations and numbers of hospital days were reduced by 44.5% (p = 0.0004) and 53.3% (p = 0.0001), respectively, with 3 mg of macitentan, and reduced by 49.8% (p < 0.0001) and 52.3% (p = 0.0003), respectively, with 10 mg of macitentan. Risk of non-PAH-related hospitalization was similar between treatment arms. CONCLUSIONS: Macitentan 10 mg significantly reduced the risk and rate of all-cause hospitalization, which was driven by reductions in the risk and rate of PAH-related hospitalization. (Study of Macitentan [ACT-064992] on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension; NCT00660179).
Actelion Pharmaceuticals Ltd Allschwil Switzerland
Cardiopulmonary Department Ignacio Chávez National Heart Institute Mexico City Mexico
Department of Cardiology CARE Hospitals Hyderabad India
Department of Medicine Imperial College London London United Kingdom
Department of Pneumology Gasthuisberg University Hospital Leuven Belgium
INSERM U 999 Centre Chirurgical Marie Lannelongue Le Plessis Robinson France
Pulmonary and Critical Care Massachusetts General Hospital Boston Massachusetts
Pulmonary Department Heart Institute University of São Paulo Medical School São Paulo Brazil
University of Giessen and Marburg Lung Center Giessen Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000500
- 003
- CZ-PrNML
- 005
- 20160126092452.0
- 007
- ta
- 008
- 160108s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jchf.2014.07.013 $2 doi
- 035 __
- $a (PubMed)25457902
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Channick, Richard N $u Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: rchannick@mgh.harvard.edu.
- 245 10
- $a Effect of macitentan on hospitalizations: results from the SERAPHIN trial / $c RN. Channick, M. Delcroix, HA. Ghofrani, E. Hunsche, P. Jansa, FO. Le Brun, S. Mehta, T. Pulido, LJ. Rubin, BK. Sastry, G. Simonneau, O. Sitbon, R. Souza, A. Torbicki, N. Galiè,
- 520 9_
- $a OBJECTIVES: This study sought to evaluate the effect of macitentan on hospitalization of patients with symptomatic pulmonary arterial hypertension (PAH). BACKGROUND: PAH is a progressive, life-threatening disease often requiring hospitalization. METHODS: In the multicenter, double-blind, randomized, event-driven, phase III SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) trial, patients with symptomatic PAH were randomized (1:1:1) to receive placebo or 3 mg or 10 mg of macitentan. Effects of macitentan on the risk, rate, and number of hospital days for all-cause and PAH-related hospitalizations were compared with those for placebo. Risk and causes of hospitalizations unrelated to PAH were investigated. RESULTS: Of 742 randomized patients, 250 received placebo, 250 received 3 mg of macitentan, and 242 received 10 mg of macitentan; the overall median duration of treatment was 115 weeks. Risk of all-cause hospitalization was reduced by 18.9% (p = 0.1208) and 32.3% (p = 0.0051) in the macitentan 3-mg and 10-mg arm, respectively. Rates of all-cause hospitalizations and numbers of hospital days were reduced by 20.5% (p = 0.0378) and 30.6% (p = 0.0278), respectively, with 3 mg of macitentan and by 33.1% (p = 0.0005) and 31.0% (p = 0.0336), respectively, with 10 mg of macitentan. Risk of PAH-related hospitalizations were reduced by 42.7% (p = 0.0015) and 51.6% (p < 0.0001) in the macitentan 3-mg and 10-mg arms, respectively. Rate of PAH-related hospitalizations and numbers of hospital days were reduced by 44.5% (p = 0.0004) and 53.3% (p = 0.0001), respectively, with 3 mg of macitentan, and reduced by 49.8% (p < 0.0001) and 52.3% (p = 0.0003), respectively, with 10 mg of macitentan. Risk of non-PAH-related hospitalization was similar between treatment arms. CONCLUSIONS: Macitentan 10 mg significantly reduced the risk and rate of all-cause hospitalization, which was driven by reductions in the risk and rate of PAH-related hospitalization. (Study of Macitentan [ACT-064992] on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension; NCT00660179).
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a antagonisté endotelinového receptoru A $x aplikace a dávkování $7 D065130
- 650 _2
- $a familiární plicní arteriální hypertenze $x farmakoterapie $x patofyziologie $7 D065627
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hospitalizace $x trendy $7 D006760
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a plicní tlak v zaklínění $x účinky léků $7 D011669
- 650 _2
- $a pyrimidiny $x aplikace a dávkování $7 D011743
- 650 _2
- $a sulfonamidy $x aplikace a dávkování $7 D013449
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Delcroix, Marion $u Department of Pneumology, Gasthuisberg University Hospital, Leuven, Belgium.
- 700 1_
- $a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; Department of Medicine, Imperial College London, London, United Kingdom.
- 700 1_
- $a Hunsche, Elke $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
- 700 1_
- $a Jansa, Pavel $u Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague, Czech Republic.
- 700 1_
- $a Le Brun, Franck-Olivier $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
- 700 1_
- $a Mehta, Sanjay $u Division of Respirology, Department of Medicine, London Health Sciences Centre-Victoria Hospital, Western University, London, Ontario, Canada.
- 700 1_
- $a Pulido, Tomás $u Cardiopulmonary Department, Ignacio Chávez National Heart Institute, Mexico City, Mexico.
- 700 1_
- $a Rubin, Lewis J $u Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical School, San Diego, California.
- 700 1_
- $a Sastry, B K S $u Department of Cardiology, CARE Hospitals, Hyderabad, India.
- 700 1_
- $a Simonneau, Gérald $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France; INSERM U-999, Centre Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France.
- 700 1_
- $a Sitbon, Olivier $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France; INSERM U-999, Centre Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France.
- 700 1_
- $a Souza, Rogério $u Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.
- 700 1_
- $a Torbicki, Adam $u Department of Pulmonary Circulation and Thromboembolic Diseases, Medical Center of Postgraduate Education, ECZ-Otwock, Poland.
- 700 1_
- $a Galiè, Nazzareno $u Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Bologna University Hospital, Bologna, Italy.
- 773 0_
- $w MED00184931 $t JACC. Heart failure. Heart failure $x 2213-1787 $g Roč. 3, č. 1 (2015), s. 1-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25457902 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20160126092615 $b ABA008
- 999 __
- $a ok $b bmc $g 1102781 $s 924706
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 3 $c 1 $d 1-8 $e 20141111 $i 2213-1787 $m JACC. Heart failure $n JACC Heart Fail $x MED00184931 $o Heart failure
- LZP __
- $a Pubmed-20160108
